---
document_datetime: 2023-09-21 21:59:42
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rapiscan-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: rapiscan-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 6.0510377
conversion_datetime: 2025-12-25 10:49:19.324255
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rapiscan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041/G            | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 30/03/2023                          |                                             | SmPC, Annex II, Labelling and PL | The SmPC section 6.1, 6.3, 6.5 has been updated as follows: • Phosphate salt excipients: hydrates deleted • 7 mL vial added, with the relevant shelf-life (2.5 years) Annex II has been updated as follows: • Addition of GE Healthcare AS ad additional manufacturer responsible for batch release The Labelling and PL have been updated accordingly. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF         |            |            |                 |                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------|
| II/0038            | Extension of indication to modify the existing indication to allow use in line with new imaging technologies that have evolved since initial approval of Rapiscan; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 11/11/2021 | 13/12/2021 | SmPC and PL     | Please refer to Scientific Discussion 'Rapiscan-H-C-001176- II-38' |
| PSUSA/2616/ 202104 | Periodic Safety Update EU Single assessment - regadenoson                                                                                                                                                                                                                                                                                                                                                            | 02/12/2021 | n/a        |                 | PRAC Recommendation - maintenance                                  |
| IAIN/0040/G        | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                            | 25/10/2021 | 13/12/2021 | Annex II and PL |                                                                    |

<div style=\"page-break-after: always\"></div>

|           | control/testing A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                 | Including batch   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------|
| IA/0037/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 19/03/2021 | 13/12/2021 | Annex II and PL | manufacturer      |
| IB/0036/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                      | 07/12/2020 | n/a        |                 |                   |

<div style=\"page-break-after: always\"></div>

| II/0034/G          | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to              | 28/11/2019   | 24/03/2020   | SmPC                   |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/2616/ 201904 | Periodic Safety Update EU Single assessment - regadenoson                                                                                                                                                                              | 31/10/2019   | n/a          |                        | PRAC Recommendation - maintenance |
| IAIN/0033          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/04/2019   | 24/03/2020   | Annex II and PL        |                                   |
| II/0027            | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                         | 13/12/2018   | 23/01/2019   | SmPC, Labelling and PL |                                   |
| PSUSA/2616/ 201804 | Periodic Safety Update EU Single assessment - regadenoson                                                                                                                                                                              | 31/10/2018   | n/a          |                        | PRAC Recommendation - maintenance |
| IAIN/0030          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                     | 11/12/2017   | n/a          |                        |                                   |
| T/0029             | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 23/11/2017   | 11/12/2017   | SmPC, Labelling and    |                                   |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                      |            |            | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                    | 07/12/2017 | 20/11/2018 | SmPC | The MAH submitted a series of in vitro studies performed to characterise the activity of regadenoson as a substrate or inhibitor of various human transporters. Regadenoson does not significantly inhibit the transporters OAT1, OAT3, OCT1, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP, ENT 1 or ENT2 at 1 µM. The data are insufficient to conclude about the risk of interactions at the level of these transporters given that a single concentration was evaluated in most instances. Regadenoson may have a modest inhibitory effect on the active renal transporter, OCT2, and has been found to be likely substrate for BCRP, ENT1 or ENT2 mediated transport. However, given the proposed duration of use, the effects of the drug transporters are unlikely to be clinically relevant. |
| IB/0028            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate         | 04/12/2017 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/2616/ 201704 | Periodic Safety Update EU Single assessment - regadenoson                                                                                                                                                            | 26/10/2017 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0024/G          | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 30/01/2017 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | data B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0023            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/12/2016 | n/a |                                   |
| PSUSA/2616/ 201604 | Periodic Safety Update EU Single assessment - regadenoson                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/10/2016 | n/a | PRAC Recommendation - maintenance |
| IA/0021            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/12/2015 | n/a |                                   |
| IB/0020/G          | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 21/12/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/2616/ 201504   | Periodic Safety Update EU Single assessment - regadenoson                                                                                                       | 06/11/2015   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2616/ 201410   | Periodic Safety Update EU Single assessment - regadenoson                                                                                                       | 21/05/2015   | 17/07/2015 | SmPC and PL           | Please refer to Rapuiscan-PSUSA/00002616/201410 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| R/0017               | Renewal of the marketing authorisation.                                                                                                                         | 26/02/2015   | 24/04/2015 | SmPC, Annex II and PL |                                                                                                                                                                  |
| IA/0016              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                            | 12/11/2014   | n/a        |                       |                                                                                                                                                                  |
| PSUV/0015            | Periodic Safety Update                                                                                                                                          | 06/11/2014   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                |
| PSUV/0014            | Periodic Safety Update                                                                                                                                          | 22/05/2014   | 22/07/2014 | SmPC and PL           | Please refer to Rapiscan EMEA/H/C/1176/PSUV/0014 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| PSUV/0013            | Periodic Safety Update                                                                                                                                          | 21/11/2013   | 16/01/2014 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0013.                                |
| IAIN/0012            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 28/10/2013   | n/a        |                       |                                                                                                                                                                  |
| IA/0011              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or        | 28/10/2013   | n/a        |                       |                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|             | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010     | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/03/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0009/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 16/01/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0006     | Update of section 4.8 of the SmPC in order to update the safety information on hypersensitivity reactions following the recommendations from the AR for the second PSUR. The Package Leaflet was updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                     | 15/11/2012 | 15/11/2013 | SmPC and PL | Based on the review of the 2nd periodic safety update report (PSUR), the CHMP recommended an update of the section 4.8 of the SmPC. The MAH proposed and the CHMP agreed to add hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis and/or throat tightness under category 'uncommon' in the adverse drug reactions table and to add the information that signs of hypersensitivity may be immediate or delayed onset. |

<div style=\"page-break-after: always\"></div>

| IAIN/0008   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                | 25/09/2012   | 29/10/2012   | Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0007     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                       | 08/08/2012   | n/a          |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0005     | Update of section 5.1 of the SmPC in order to update the safety information following the results of two clinical studies: 3606-CL-3001 and 3606-CL-3002. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/02/2012   | 21/03/2012   | SmPC              | Study 3606 CL-3001 was assessing the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. In this study dyspnoea was reported more frequently following Rapiscan (18% for patients with COPD; 11% for patients with asthma) than placebo, but at a lower rate than reported during clinical development however the use of bronchodilator therapy for symptoms was not different between Rapiscan and placebo. Section 5.1 of the SmPC was updated accordingly. Study 3606 CL-3002 was assessing the effect of caffeine intake on single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in subjects administered Regadenoson. The assessment of this study led to a conclusion that caffeine compromised the diagnostic accuracy of detecting reversible perfusion defects and resulted in modifications of section 5.1 of the SmPC. |
| II/0002     | The CHMP considered that the Detailed Description of the Pharmacovigilance System for Rapiscan fulfils the requirements and was acceptable.                                                                                                                                                                      | 22/09/2011   | 27/10/2011   | Annex II          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH                                                                                                                                |            |            |                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0004   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                         | 28/06/2011 | n/a        | SmPC                   |
| IA/0003/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.b.2 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing | 27/04/2011 | n/a        | Annex II and PL        |
| T/0001    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                               | 24/11/2010 | 11/01/2011 | SmPC, Labelling and PL |